💊

GLENMARK

initiates Phase 3 Clinical Trial for Envafolimab

has launched a multi-country (ex-China) Phase 3 clinical trial for Envafolimab, a novel subcutaneous PD-L1 inhibitor, in patients with resectable Stage III NSCLC (Non-Small Cell Lung Cancer). 📍 Key Highlights: ✅ DCGI approval secured for patient enrolment & dosing in India ✅ Clinical Trial Application submitted in Russia ✅ Trial sites being prepared in Brazil & Mexico, enhancing global reach ✅ Randomized, multi-center Phase 3 trial to assess efficacy, safety, PK, and immunogenicity 🌍 With lung cancer being the leading cause of cancer-related deaths globally, and NSCLC accounting for ~80–85% of cases, the urgent need for effective immunotherapy is critical. Envafolimab holds the potential to improve long-term outcomes for patients with Stage IIIA & IIIB NSCLC, where current five-year survival rates remain low. As a research-led global pharma company operating in 50+ countries, Glenmark continues to strengthen its oncology innovation pipeline with the aim of delivering impactful therapies to patients worldwide.